FLTWL derived peptide, polypeptide and polypeptide drug

Through the binding of FLTWL-derived peptides to TAF4 and Mediator complexes, the transcriptional activity of cancer cells is inhibited, the problem of anti-cancer drug resistance is solved, and effective inhibition of cancer cells and tumor growth control is achieved.

CN118894904APending Publication Date: 2024-11-05HUAWEI CLOUD COMPUTING TECHNOLOGIES CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310893961.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2023-07-19
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing anti-cancer drug resistance issues, especially the resistance of EGFR-TKI, have led to weakening cancer cells' response to treatment, and new anti-cancer drugs need to be developed to solve this problem.

Method used

A FLTWL-derived peptide, polypeptide, polypeptide drug is developed to restrict its transcriptional activity in cancer cells by binding to proteins in the transcription initiating factor TAF4 and Mediator complex, thereby inhibiting the proliferation and growth of cancer cells. This polypeptide drug can enter the cell nucleus and bind to MED15 and TAF4 to inhibit the expression of target genes and achieve anti-tumor effects.

Benefits of technology

Effectively inhibit the proliferation and growth of cancer cells, reduce the semi-inhibitory concentration of polypeptide drugs, significantly improve the inhibitory effect on cancer cells, solve the problem of tumor drug resistance, and show anti-tumor effects in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894904A_ABST
    Figure CN118894904A_ABST
Patent Text Reader

Abstract

The invention discloses FLTWL derived peptides, polypeptides and polypeptide drugs. Relates to the technical field of biological medicine. The FLTWL-derived peptide comprises: a first amino acid; the first amino acid has the same serial number as one amino acid in the FLTWL, and the amino acid having the same serial number as the first amino acid in the FLTWL is different from the first amino acid; the FLTWL derived peptide has an amino acid sequence similar to that of FLTWL; and the FLTWL derived peptide interacts with at least one protein of TAF4 and MED15. The FLTWL-derived peptide disclosed by the invention interacts with at least one protein of TAF4 and MED15, namely, the FLTWL-derived peptide can be combined with at least one protein of TAF4 and MED15. When the FLTWL derived peptide is combined with the TAF4, the function of the TAF4 in the transcription starting process of a target gene (in cancer cells) can be limited, and then the purpose of inhibiting proliferation and growth of the cancer cells is achieved. When the FLTWL derived peptide is combined with the MED15, the effect of the MED15 in the transcription extension process of a target gene in cancer cells is limited, so that the aim of inhibiting proliferation and growth of the cancer cells is fulfilled.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the priority of the Chinese patent application filed with the State Intellectual Property Office on May 4, 2023, with application number: 2023104927523. The application name is "Transcription activator YAP / TAZ polypeptide drug with anti-tumor effect and its derivatives", the entire content of which is incorporated by reference in this application. Technical Field

[0002] The present invention belongs to the field of biomedicine technology, and in particular relates to a FLTWL-derived peptide, polypeptide, and polypeptide drug. Background Art

[0003] Cancer, also known as tumor, is a disease. One of the reasons for the occurrence of cancer is that due to the abnormal growth and division of cells, they are transformed into cancer cells, which can invade surrounding tissues and organs and spread to other parts through the blood and lymphatic system.

[0004] Currently available anticancer drugs use epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) to block the activity of tyrosine kinase, thereby achieving the purpose of inhibiting the growth of cancer cells. Summary of the invention

[0005] The present application discloses a FLTWL-derived peptide, polypeptide, and polypeptide drug. The FLTWL-derived peptide has a similar amino acid structure to FLTWL, and the FLTWL-derived peptide can interact with at least one of TAF4 and MED15 proteins to achieve the purpose of inhibiting the growth of cancer cell proliferation.

[0006] In a first aspect, the present application discloses a FLTWL-derived peptide, which comprises: a first amino acid; the first amino acid has the same sequence number as an amino acid in FLTWL, and the amino acid in FLTWL that has the same sequence number as the first amino acid is different from the first amino acid; the FLTWL-derived peptide interacts with at least one of the transcription initiation factor binding protein TAF4 and the recombinant protein MED15; the FLTWL-derived peptide interacts with at least one of the proteins TAF4 and MED15.

[0007] The FLTWL-derived peptide disclosed in the present application has a similar amino acid sequence to FLTWL. The FLTWL-derived peptide interacts with at least one of TAF4 and MED15 proteins, that is, the FLTWL-derived peptide can bind to at least one of TAF4 and MED15 proteins.

[0008] When the FLTWL-derived peptide binds to TAF4, it can limit the role of TAF4 in the transcription initiation process of the target gene (in cancer cells), thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0009] When the FLTWL-derived peptide binds to MED15, it limits the role of MED15 in the transcriptional elongation of target genes in cancer cells, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0010] The FLTWL-derived peptide disclosed in the present application is a new type of peptide chain. The FLTWL-derived peptide can be used in tumor drugs and can solve the problem of drug resistance of currently disclosed tumor drugs.

[0011] In conjunction with an implementation of the first aspect, the FLTWL-derived peptide further comprises: a second amino acid core and a third amino acid; the second amino acid has the same sequence number as an amino acid in FLTWL; the amino acid in FLTWL having the same sequence number as the second amino acid is the same as the second amino acid;

[0012] The third amino acid has the same sequence number as an amino acid in FLTWL; the amino acid in FLTWL having the same sequence number as the third amino acid is the same as the third amino acid. In one implementation of the first aspect, FLTWL is contained in the C-terminal amino acid sequence of the transcription coactivator protein YAP in the 450-504 domain.

[0013] In combination with an implementation of the first aspect, FLTWL is contained in the C-terminal amino acid sequence of the transcription co-activator protein TAZ in the 450-504 domain.

[0014] In combination with an implementation of the first aspect, the amino acid sequence of the FLTWL-derived peptide includes any one of FLTFL, DLTWL, ELTWL, FWTWL, FITWL, FLEWL, and FLDWL.

[0015] The FLTWL-derived peptide disclosed in the present implementation can bind to at least one of the proteins MED15 and TAF4, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0016] The second aspect of the present application discloses a polypeptide, comprising: a nuclear localization signal peptide and the FLTWL-derived peptide disclosed in the first aspect, wherein the FLTWL-derived peptide is located at at least one of the N-terminus of the nuclear localization signal peptide and the C-terminus of the nuclear localization signal peptide;

[0017] Or, the polypeptide includes: a nuclear localization signal peptide and a hydrophobic polypeptide, the hydrophobic peptide is located at at least one of the N-terminus of the nuclear localization signal peptide and the C-terminus of the nuclear localization signal peptide, and the hydrophobic polypeptide has the amino acid sequence of FLTWL.

[0018] The polypeptide disclosed in the present implementation method includes: a nuclear localization signal peptide, which can guide the FLTWL-derived peptide / FLTWL (which can be understood as FLTWL-derived peptide or FLTWL) into the cell nucleus, so that the FLTWL-derived peptide / FLTWL can bind to at least one protein of MED15 and TAF4 located in the cell nucleus, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0019] In combination with an implementation method of the second aspect, the amino acid sequence of the polypeptide includes any one of PKKKRKVFLTWL, FLTWLPKKKRKV, FLTWLPKKKRKVFLTWL, DLTWLPKKKRKVDLTWL, ELTWLPKKKRKVELTWL, FWTWLPKKKRKVFWTWL, FLEWLPKKKRKVFLEWL, and FLDWLPKKKRKVFLDWL.

[0020] The polypeptide disclosed in the present implementation can enter the cell nucleus and bind to at least one protein of MED15 and TAF4 located in the cell nucleus, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0021] The third aspect of the present application discloses a polypeptide drug, which may include: liposomes and the polypeptide disclosed in the second aspect; the liposomes encapsulate the polypeptide.

[0022] The polypeptide drug disclosed in the present implementation method includes: liposomes and polypeptides. The polypeptide is inserted into the liposome. The structure of the liposome is similar to the cell membrane of cancer cells. The liposome can carry the polypeptide inside it into the cell. In the process of crossing the cell membrane, the liposome is dissolved by the cell membrane, and the polypeptide inside the liposome is released into the cell. The polypeptide located in the cell can enter the cell nucleus under the guidance of the nuclear localization signal peptide and bind to at least one protein of MED15 and TAF4 located in the cell nucleus, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0023] In combination with an implementation of the third aspect, the half inhibitory concentration (ITJ-C50) of the polypeptide drug on cancer cells is less than or equal to 27.73 μM.

[0024] The ITJ-C50 of the polypeptide drug disclosed in the present implementation can reach below 27.73 μM. The polypeptide drug has a lower ITJ-C50 and has a significant inhibitory effect on cancer cells.

[0025] In conjunction with an implementation of the third aspect, the polypeptide drug is used to inhibit the proliferation of cancer cells.

[0026] In conjunction with an implementation of the third aspect, the polypeptide drug is used to inhibit the growth of cancer cells.

[0027] In conjunction with an implementation of the third aspect, the polypeptide drug is used to inhibit the expression of a target gene, and the target gene includes at least one of ANKRD1, CTGF, and CYR61.

[0028] The polypeptide drug disclosed in this implementation can inhibit the expression of target genes of cancer cells. It can be further inferred that the polypeptide drug disclosed in this implementation can inhibit the proliferation and growth of cancer cells.

[0029] In combination with an implementation of the third aspect, the polypeptide drug is used to inhibit tumor growth.

[0030] In combination with an implementation of the third aspect, the cancer cells include at least one of adenocarcinoma cells, colorectal cancer cells, and liver cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 is a schematic diagram of the amino acid sequence of YAP;

[0032] Figure 2 is a schematic diagram of the amino acid sequence of TAF4;

[0033] Figure 3 A diagram showing the results of a protein immunoblotting experiment of YAP and TAF4 disclosed in a feasible embodiment;

[0034] Figure 4 A diagram showing the results of a protein imprinting experiment of YAP and TAF4 disclosed in a feasible embodiment;

[0035] Figure 5 A diagram showing the results of a protein imprinting experiment of YAP and TAF4 disclosed in a feasible embodiment;

[0036] Fig. 6A A diagram showing the results of an NMR titration experiment of YAP and TAF4 disclosed in a feasible embodiment;

[0037] Figure 6B A diagram showing the results of an NMR titration experiment of YAP and TAF4 disclosed in a feasible embodiment;

[0038] Figure 7 A diagram showing the results of a protein imprinting experiment of a YAP and Mediator family complex is disclosed as a feasible embodiment;

[0039] Figure 8 A feasible embodiment discloses the results of a protein imprinting experiment of YAP and MED15;

[0040] Fig. 9 is a schematic diagram of the amino acid sequence of MED15;

[0041] Fig. 10A A feasible embodiment disclosed 15 Experimental results of NMR titration of N-YAP-sTAD (titrants) and ABD3 (titrants);

[0042] Fig. 10B A feasible embodiment disclosed 15 Experimental results of NMR titration of N-YAP-sTAD (titrants) and ABD3 (titrants);

[0043] Fig.11A YAP-sTAD (titrant) disclosed in a feasible embodiment and 15 Results of NMR titration experiment of N-MED15-ABD3 (titrants);

[0044] Fig. 11B YAP-sTAD (titrant) disclosed in a feasible embodiment and 15 Results of NMR titration experiment of N-MED15-ABD3 (titrants);

[0045] Fig. 12A FLTWL (titrant) disclosed as a feasible embodiment and 15 Results of NMR titration experiment of N-MED15-ABD3 (titrants);

[0046] Fig. 12B FLTWL (titrant) disclosed as a feasible embodiment and 15 Results of NMR titration experiment of N-MED15-ABD3 (titrants);

[0047] Fig.13 The figure shows the test results of ITJ-C50 of several peptide drugs based on CCK8;

[0048] Fig.14 This is a result diagram of the immunofluorescence experiment to detect the effect of H1299 on the uptake of peptide drug TJ-M11;

[0049] Fig.15 This is a result diagram of detecting the effect of H1299 on the uptake of peptide drug TJ-C8 by immunofluorescence experiment;

[0050] Fig.16 This is the result diagram of target gene mRNA expression after adding peptide drug TJ-M11;

[0051] Fig.17A This is an image of H1299 obtained by a plate cloning experiment disclosed in a feasible embodiment;

[0052] Fig. 17BIt is a bar graph of the number of clones of H1299;

[0053] Fig.18A This is an image of TDCL obtained by a plate cloning experiment disclosed in a feasible embodiment;

[0054] Fig.18B It is a bar graph of the clone number of TDCL;

[0055] Fig.19 The test results of peptide drugs based on CCK8 on several cancer cells ITJ-C50 are shown in the figure;

[0056] Fig. 20A Tumor images of the experimental and control groups;

[0057] Fig. 20B This is a statistical diagram of the difference in tumor volume between the experimental group and the control group within 20 days of drug administration;

[0058] Fig. 20C This is a statistical graph showing the difference in tumor weight between the experimental group and the control group within 20 days of drug administration. DETAILED DESCRIPTION

[0059] The technical solutions in the embodiments of the present application will be described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all of the embodiments.

[0060] In the following, the terms "first", "second", etc. are used only for descriptive purposes to distinguish between identical or similar items with substantially identical functions and effects, and are not to be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Thus, a feature defined as "first", "second", etc. may explicitly or implicitly include one or more of the features.

[0061] Also, in the description of the present application, unless otherwise specified, “plurality” means two or more than two.

[0062] Meanwhile, in the embodiments of the present application, words such as "exemplary" or "for example" are used to indicate examples, illustrations or descriptions. Any embodiment or design described as "exemplary" or "for example" in the embodiments of the present application should not be interpreted as being more preferred or more advantageous than other embodiments or designs. Specifically, the use of words such as "exemplary" or "for example" is intended to present related concepts in a concrete manner for ease of understanding.

[0063] First, the concepts involved in the embodiments of the present application are explained:

[0064] A peptide chain (polypeptide) can be understood as a compound formed by two or more amino acids linked together by peptide bonds. A peptide chain is an intermediate product of protein hydrolysis. One end of the peptide chain has a free amino group (-NH2), and the other end of the peptide chain has a free carboxyl group (-COOH). The hydrophobic peptides, polypeptides, derivative peptides, and nuclear localization signal peptides involved in the embodiments of the present application are all peptide chains, and the end of the peptide chain with a free amino group can be referred to as the N-terminus, and the end with a free carboxyl group can be referred to as the C-terminus.

[0065] A derivative peptide can be understood as a peptide chain obtained by mutating at least one amino acid in a polypeptide (reference peptide). The amino acid sequence of the derivative peptide has obvious similarity with that of the reference peptide.

[0066] Nuclear localization signal (NLS), also known as nuclear localization sequence, refers to a short amino acid sequence that can guide proteins / peptides into the cell nucleus.

[0067] Amino acid can be understood as an organic compound containing a basic amino group and an acidic carboxyl group. Amino acid is the basic unit of protein / polypeptide. The amino acids involved in the embodiments of the present application can be found in Table 1.

[0068] Table 1

[0069] Full name abbreviation Chinese name Hydrophilicity / hydrophobicity Val V Valine Hydrophobicity Leu L Leucine Hydrophobicity Ile I Isoleucine Hydrophobicity Phe F Phenylalanine Hydrophobicity Trp W Tryptophan Hydrophobicity Lys K Lysine Hydrophilicity Thr T Threonine Hydrophilicity Cys C Cysteine Hydrophilicity Pro P Proline Hydrophobicity

[0070] Protein can be understood as an important component of all cells and tissues. All important components of the body require the participation of protein.

[0071] A domain is a layer between the supersecondary structure and the tertiary structure. A domain is an independent folding unit within the tertiary structure of a protein, usually a combination of several supersecondary structure units.

[0072] Epidermal growth factor receptor (EGFR) is one of the most common driver genes in cancer cells.

[0073] Drug resistance, also known as drug resistance, can be understood as the tolerance of cancer cells to the effects of anticancer drugs. Once drug resistance occurs, the therapeutic effect of anticancer drugs will be significantly reduced.

[0074] Homologous proteins can be understood as proteins with obvious similarity in amino acid sequences that perform the same or similar functions in different organisms or the same organism. The Yes-associated protein (YAP) and recombinant protein (tafazzin, TAZ) involved in the embodiments of the present application can be understood as homologous proteins.

[0075] The target gene (gene of interest) can be understood as a gene involved in the growth and proliferation of cancer cells. The target genes may include: connective tissue growth factor (CTGF), homocysteine ​​protein 61 (CYR61), ankyrin repeat domain protein 1 (ANKRD1), etc.

[0076] The cancer cells involved in the embodiments of the present application include: lung cancer cells include: mouse lung cancer cells (DTCL), human lung cancer cells (H1299).

[0077] Cancer is a disease that can occur in various parts of the human body. Cancer occurs due to the abnormal growth and division of human cells, which can invade surrounding tissues and organs and spread to other parts through the blood and lymphatic systems. Cancer can include: benign tumors and malignant tumors. Therefore, in the embodiments of the present application, cancer can also be referred to as a tumor.

[0078] Among them, benign tumors usually do not cause harm to the human body, but if the size of a benign tumor is large, it may cause compression or damage to surrounding tissues and organs.

[0079] Malignant tumors can cause serious harm to the human body because they can invade surrounding tissues and organs and spread to other parts through the blood and lymphatic systems. In addition, malignant tumors can also affect the normal functions of the human body by producing toxins and metabolites.

[0080] According to statistics, there were approximately 18.1 million new cancer cases and 9.6 million cancer deaths worldwide in 2018. Among many cancers, lung cancer ranks at the top in terms of incidence, mortality, new cases, and deaths.

[0081] Cancer statistics in 2018 show that the incidence of lung cancer is as high as 11.6%. The mortality rate of lung cancer is as high as 18.4%. There are 2.094 million new cases of lung cancer. There are 1.761 million deaths from lung cancer. Among them, Asia has 48.4% of new cases of lung cancer and 57.3% of deaths. The proportion is the highest in the world, with China accounting for the highest proportion. According to the 2018 analysis report of the International Agency for Research on Cancer, the incidence of lung cancer is 22.48 / 100,000 (2.094 million new patients per year), and the mortality rate is 18.51 / 100,000 (1.761 million new deaths per year), ranking first in both incidence and mortality.

[0082] Treatment options for cancer vary depending on the type and location of the cancer. Common cancer treatment options include:

[0083] (1) Surgery. Surgical treatment of cancer can be understood as the removal of the tumor and the tissues and organs around the tumor to achieve the purpose of curing cancer.

[0084] (2) Chemotherapy. Chemotherapy for cancer treatment can be understood as the use of chemical drugs (anti-cancer drugs) to kill cancer cells.

[0085] (3) Radiotherapy. Radiotherapy for cancer can be understood as the use of high-energy radiation to kill cancer cells.

[0086] (4) Immunotherapy: Immunotherapy for cancer can be understood as killing cancer cells by activating the human immune system.

[0087] (5) Targeted therapy: Targeted therapy can be understood as the use of targeted drugs to treat target genes of cancer cells.

[0088] Taking lung cancer positive patients as an example, the EGFR gene of lung cancer positive patients may be mutated, and the EGFR gene may include: exon 19, exon 21 L858R and L861Q, exon 18 G719X, and exon 20 S768I.

[0089] Currently, the anticancer drugs used to treat lung cancer positive patients are mainly EGFR-TKI. For example, pemetrexed + platinum + bevacizumab is a typical EGFR-TKI. However, EGFR-TKI resistance is a common problem.

[0090] The development of drug resistance to anticancer drugs forces people to continue to develop new anticancer drugs. It has been documented in related technologies that cancer involves multiple signal pathways. Among them, signal pathways can be understood as the phenomenon that when a certain reaction occurs in a cell, a signal transmits a message from outside the cell to inside the cell, and the cell responds according to this message.

[0091] The Hippo signaling pathway is a signaling pathway originally discovered in Drosophila. The Hippo signaling pathway consists of a series of cascade kinases. In mammals, the core components of the Hippo signaling pathway include: protein kinase MST1 / 2 antibodies (STE20-like kinase, MST1 / 2), Salvador homolog (salvador protein salvador homolog1, SAV1), serine / threonine protein kinase (Serine / threonine-protein kinase, LATS1 / 2), kinase activator (kinase activator 1, MOB1), transcriptional co-activator YAP / TAZ, etc. These components regulate each other to form a protein phosphorylation network.

[0092] The Hippo signaling pathway is further described below:

[0093] (1) Once the protein phosphorylation network senses the upstream activation signal, the downstream MST1 / 2 is phosphorylated and activates LATS1 / 2 with the help of SAV1 as a kinase and MOB1 as a cofactor.

[0094] (2) Activated LATS1 / 2 kinases inactivate YAP / TAZ by phosphorylating it to promote its cytoplasmic localization and degradation. Unphosphorylated YAP / TAZ will enter the nucleus and accumulate in the nucleus.

[0095] (3) YAP / TAZ accumulated in the cell nucleus can bind to transcriptional enhancer-associated domain proteins (TEAD family, TEADs), thereby initiating the expression of target genes. That is, the transcriptional coactivator YAP / TAZ and TEADs form a signaling pathway (YAP / TAZ-TEADs). Specifically, the binding of YAP / TAZ to TEADs can control the expression of target genes, regulate the proliferation and growth of cancer cells, and thus achieve the purpose of cancer treatment.

[0096] The Hippo signaling pathway has been reported to be involved in many physiological and pathological processes such as tissue homeostasis regulation, organ size control, and tumor occurrence and development. In the Hippo signaling pathway, transcriptional coactivators YAP / TAZ, as key effector molecules, can participate in many biological processes such as tissue homeostasis regulation, organ size control, and tumor occurrence and development.

[0097] Related technology has been made public: YAP / TAZ activation has been found in the cytoplasmic red cells of various cancers, including liver cancer, colon cancer, and breast cancer.

[0098] Related technologies also disclose that the proportion of YAP is upregulated in lung cancer, medulloblastoma, pancreatic cancer, esophageal cancer, liver cancer and breast cancer.

[0099] Related technologies further disclose that YAP / TAZ can participate in promoting cancer cell proliferation, anti-apoptosis, tumor stem cells, angiogenesis, drug resistance and tumor immunity.

[0100] Based on the above-mentioned related technical disclosures, it can be inferred that the transcriptional coactivator YAP / TAZ is involved in almost every process of cancer. By exploring the binding region of YAP / TAZ with downstream proteins and designing anticancer drugs targeting the binding region, a new treatment option for cancer can be provided.

[0101] Next, we explore the binding regions of the transcriptional co-activators YAP / TAZ and downstream proteins.

[0102] It is worth noting that YAP and TAZ are homologous proteins, and the amino acid sequences of YAP and TAZ have obvious similarities. The implementation method of exploring the binding region of TAZ and downstream proteins is similar to the implementation method of exploring the binding region of YAP and downstream proteins. In the subsequent examples, the exploration process of the binding region of YAP is selected to illustrate:

[0103] In order to more accurately locate the binding area between YAP and downstream proteins, YAP can be divided into multiple domains in advance.

[0104] Considering that YAP is a homologous protein to Yki in Drosophila, as a feasible implementation method, YAP can be divided into three domains according to the domain division method of Yki disclosed in the relevant technology. The specific division results can be found in Figure 1 (a) in.

[0105] The amino acid sequence of the C-terminal transcription activation domain (TAD) of YAP is divided into:

[0106] (1) Coiled coil domain (CC). The amino acid sequence of CC in YAP is 298-359.

[0107] (2) Intrinsically disordered protein (sIDP) domain. The amino acid sequence of sIDP in YAP is 360-449.

[0108] (3) sTAD, the amino acid sequence of sTAD in YAP is between 450 and 540.

[0109] The present application also cuts off / removes different structures of YAP. For details, please refer to Figure 1 (II) Figure 1 in (3), Figure 1 (IV) in.

[0110] YAP with sTAD truncated can be expressed as: YAP△TAD. The amino acid sequence of YAP△TAD can be found in Figure 1 (ii) in.

[0111] YAP with IDR truncated can be expressed as: YAP△sIDR. The amino acid sequence of YAP△sIDR can be found in Figure 1 Of (3).

[0112] YAP with CC truncated can be expressed as: YAP△CC. The amino acid sequence of YAP△CC can be found at Figure 1 (IV) in.

[0113] The present application example uses experiments to locate the binding area of ​​YAP and downstream proteins. Based on this binding area, a polypeptide drug is designed to achieve the purpose of inhibiting cancer cell proliferation and growth. The present application example selects two downstream proteins: transcription initiation factor binding protein (transcription initiation factor TFIID subunit 4, TAF4) and RNA polymerase II transcription mediator (Mediator) family complex.

[0114] The following is an explanation of the process of locating the binding regions of YAP and TAF4 / Mediator family members:

[0115] TAF4 is a subunit of the transcription initiation complex (TFIID), and TFIID plays a core role in the transcription initiation process. By studying the binding region of YAP and TAF4, peptide drugs can be designed based on this binding region so that peptide drugs can bind to TAF4 and limit the role of TAF4 in the transcription initiation process of the target gene, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0116] As a feasible implementation method, we can explore the binding region of YAP and TAF4 and design peptide drugs based on this binding region to achieve the purpose of inhibiting the proliferation and growth of cancer cells.

[0117] In order to locate the binding region of TAF4 and YAP, the present embodiment divides TAF4 into 4 domains. For the specific division method, please refer to Figure 2 (a) and Figure 2 In (ii), the four domains of TAF4 are:

[0118] (1) N domain. In the examples of the present application, the N domain can be represented as: TAF4-N, abbreviated as N. The amino acid sequence of N in TAF4 is: 1-373.

[0119] (2) The M1 domain can be represented as TAF4-M1 in the examples of the present application, abbreviated as M1. The amino acid sequence of M1 in TAF4 is 374-582.

[0120] (3) The M2 domain can be represented as TAF4-M2 in the examples of the present application, abbreviated as M2. The amino acid sequence of M2 in TAF4 is 583-837.

[0121] (4) The C domain can be represented in the examples of the present application as: TAF4-C, abbreviated as C. The amino acid sequence of C in TAF4 is 838-1086.

[0122] The following specific experiments are used to locate the binding area between YAP and TAF4.

[0123] As a feasible approach, protein immunoblotting can be used to locate the binding region of YAP and TAF4.

[0124] Protein immunoblotting is also called protein blotting. It is a commonly used protein detection method. Protein immunoblotting can detect the presence and relative amount of specific proteins in mixed proteins, and can also determine the binding between proteins.

[0125] The results of the protein imprinting experiment can be reflected in the electrophoresis pattern. In the electrophoresis pattern involved in the embodiment of the present application:

[0126] (1) The ordinate is the relative amount of protein, and the abscissa is protein.

[0127] (2) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an internal reference. If the relative amounts of the internal reference in different bands are the same, it can be understood that the protein blotting experiment has good accuracy.

[0128] (3) The protein imprinting experiment involves two protein tags: Flag protein tag and HA protein tag. Among them, the Flag protein tag can be referred to as Flag in the present embodiment; the HA protein tag can be referred to as HA in the present embodiment.

[0129] (4) IP: HA can be understood as the enrichment of HA-tagged proteins.

[0130] (5) IP: Flag can be understood as enrichment of Flag-tagged proteins.

[0131] (6) Green fluorescent protein (GFP).

[0132] (7) The positive control (input) can be understood as a protein mixture that has not been enriched.

[0133] In combination with Examples 1 to 3, the process of using a protein immunoblotting experiment (also referred to as an electrophoresis test in the present application examples) to locate the binding region of YAP and TAF4 is described below:

[0134] Embodiment 1:

[0135] In this example, a protein immunoblotting experiment was used to explore the binding of YAP and TAF4. The experimental results can be found in Figure 3 . Figure 3 (a) in the figure is the experimental result of the positive control.

[0136] In this embodiment, YAP is marked with a Flag. Figure 3 In the Figure 3 It can be expressed as HA-TAF4.

[0137] See also Figure 3 In (II):

[0138] Band 31: GFP was pre-adsorbed on the electrophoresis membrane. GFP was labeled with Flag, so Flag could be detected in band 31. No HA was detected in band 31, indicating that GFP did not bind to HA-labeled YAP, that is, there was no interaction between GFP and YAP.

[0139] Zone 32: TAF4-M1 was pre-adsorbed on the electrophoresis membrane, so Flag can be detected in zone 32. HA can be detected in zone 32, which shows that TAF4-M1 binds to YAP, that is, TAF4-M1 and YAP interact with each other.

[0140] Zone 33: TAF4-M2 was pre-adsorbed on the electrophoresis membrane, so Flag can be detected in zone 33. HA can be detected in zone 33, which shows that TAF4-M2 binds to YAP, that is, TAF4-M2 and YAP interact with each other.

[0141] Zone 34: TAF4-C was pre-adsorbed on the electrophoresis membrane, so Flag could be detected in zone 34. No HA was detected in zone 34, indicating that TAF4-C did not bind to HA-tagged YAP, that is, there was no interaction between TAF4-C and YAP.

[0142] Combination Figure 3 The published experimental results show that YAP can bind to TAF4-M1, and YAP can also bind to TAF4-M2. The binding regions of TAF4 and YAP include TAF4-M1 and TAF4-M.

[0143] Embodiment 2:

[0144] In order to further locate the binding area of ​​YAP and TAF4. The present application example uses a protein imprinting experiment to further explore the binding of different domains of YAP with TAF4. For specific experimental results, please refer to Figure 4 .

[0145] This example tests respectively: the binding of YAP to TAF4; the binding of TAF4 to YAP△sTAD.

[0146] It should be noted that: from the experimental results of Example 1, it can be seen that the binding region of TAF4 and YAP is located in TAF4-M1 and TAF4-M2. TAF4-N can be considered as an inactive domain in this example. Therefore, in the examples of this application, the TAF4 used is TAF4 with TAF4-N truncated. TAF4 with TAF4-N truncated can be represented by TAF4-v in this example. The amino acid sequence of TAF4-v can be found in Figure 2 In (III), TAF4-v retains TAF4-M1 and TAF4-M2. Therefore, TAF4-v can bind to YAP.

[0147] In this embodiment, HA is used to label YAP, HA is used to label YAPΔsTAD, and Flag is used to label TAF4-v.

[0148] Figure 4 (a) in the figure is the experimental result of the positive control.

[0149] See also Figure 4 In (II):

[0150] Band 41 (test electrophoresis using single protein YAP): TAF4-v was pre-adsorbed on the electrophoresis membrane, and Flag could be detected in band 41. HA could be detected in band 41, indicating that TAF4-v bound to YAP and that there was an interaction between TAF4-v and YAP.

[0151] Band 42 (test electrophoresis using single protein YAP△sTAD): No HA was detected in band 42, indicating that TAF4-v did not bind to YAP△sTAD. It can be seen that after sTAD was intercepted, the interaction between YAP and TAF4 was destroyed.

[0152] Combination Figure 4 The published experimental results show that TAF4-v can bind to YAP, but cannot bind to YAP△sTAD. It can be inferred that the binding region of YAP and TAF4 includes sTAD.

[0153] Embodiment 3:

[0154] In order to further determine the binding area of ​​YAP and TAF4. In the present embodiment, a protein imprinting experiment was used to further locate the binding of TAF4 to each domain in sTAD. For specific experimental results, please refer to Figure 5 .

[0155] This example tests the binding of TAF4 to YAP△PDZ. YAP△PDZ is YAP with PDZ cut off, and PDZ is located at the tail end of sTAD.

[0156] In this example, HA was used to label YAP, HA was used to label YAPΔTAD, and Flag was used to label TAF4-v.

[0157] Figure 5 (a) in the figure is the experimental result of the positive control.

[0158] See also Figure 5 In (II):

[0159] Band 51 (test electrophoresis using single protein YAP): TAF4-v was pre-adsorbed on the electrophoresis membrane of band 51, and Flag could be detected on band 51. HA could be detected in band 51, indicating that TAF4-v was bound to YAP.

[0160] Band 52 (test electrophoresis using single protein YAP△PDZ): No HA was detected in band 52, indicating that TAF4-v did not bind to YAP△PDZ. It can be seen that after the PDZ domain was cut, the interaction between YAP and TAF4 was destroyed.

[0161] Combination Figure 5 The published experimental results show that TAF4-v can bind to YAP, but cannot bind to YAP△PDZ. It can be inferred that the binding region of YAP and TAF4 includes PDZ.

[0162] Combining the experimental results of Example 1 to Example 3, it can be seen that the binding region of YAP and TAF4 includes: PDZ.

[0163] Nuclear magnetic resonance (NMR) titration experiment is a commonly used analytical chemistry technique that can be used to determine the resonance absorption peaks of hydrogen (H) and nitrogen (N) in proteins, and to obtain the chemical shift of H or N based on the resonance absorption peaks.

[0164] Chemical shift can be understood as the difference between the peak position of the element resonance absorption peak and the reference. Chemical shift can characterize the binding between proteins. If binding occurs between proteins, H and N in the protein will produce chemical shift.

[0165] The following is an NMR titration experiment to locate the binding region of YAP and TAF4:

[0166] Embodiment 4:

[0167] This example uses 0.1 mM 15 N-YAP-sTAD( 15 N-labeled YAP-sTAD) was used as the titrant. TAF4-M2 was used as the titrant. 15 N-YAP-sTAD 1 H and 15 N-heteronuclear singular quantum correlation / element resonance absorption peak position (heteronuclear singular quantum correlation, HSQC), experimental results can be found at Fig. 6A and Figure 6B .

[0168] exist Fig. 6A In this example, YAP-sTAD:TAF4-M2 can be understood as the molar concentration ratio of YAP-sTAD to TAF4-M2. This example tests the molar ratios of YAP-sTAD to TAF4-M2 as 1:0, 1:0.5, 1:1, 1:2, and 1:4, respectively. 15 N-YAP-sTAD 1 H and 15 The resonance absorption peak position of N.

[0169] When the molar ratio of YAP-sTAD to TAF4-M2 is 1:0, YAP-sTAD and TAF4-M2 do not bind to each other, and the resonance absorption peak position at this time can be used as a benchmark.

[0170] from Fig. 6A It can be seen that after adding TAF4-M2, 15 N-YAP-sTAD1 H and 15 N all underwent chemical shifts, and with the increase of TAF4-M2 molar concentration, 1 H and 15 The change in N chemical shift gradually increased. It can be inferred that after the addition of TAF4-M2, YAP-sTAD and TAF4-M2 were bound, resulting in 15 N-YAP-sTAD 1 H and 15 N undergoes chemical shift.

[0171] Please continue reading Fig. 6A , phenylalanine (F500) with amino acid sequence 500, leucine (L501) with amino acid sequence 501, threonine (T502) with amino acid sequence 502, tryptophan (W503) with amino acid sequence 503, and leucine (L504) with amino acid sequence 504 15 The chemical shift of N and 1 The chemical shift of H changes significantly. It can be seen that the domain of YAP amino acid sequence at 500-504 binds to TAF4, that is, the binding region of YAP and TAF4 includes the domain of YAP amino acid sequence at 500-504. It is worth noting that 15 The sequence of each amino acid in N-YAP-sTAD refers to the sequence of amino acids in YAP.

[0172] The amino acids contained in the domain 500-504 of the YAP amino acid sequence include: F, L, T, W, L. Therefore, in the embodiment of the present application, the domain 500-504 of the YAP amino acid sequence can be expressed as: FLTWL. FLTWL is a hydrophobic polypeptide (short linear motifs, SLiMs). Therefore, in the embodiment of the present application, FLTWL can also be referred to as a hydrophobic polypeptide.

[0173] Figure 6B This is the result of NMR titration experiment (YAP-sTAD:TAF4-M2=1:4). Figure 6B The horizontal axis is the sequence of each amino acid in YAP-sTAD; the vertical axis is the change in peak intensity before and after titration. It can be seen that the peak intensity of the amino acids in the amino acid sequence of 500-504 has changed, which can further verify that the binding area of ​​YAP and TAF4 includes the domain of the amino acid sequence of 500-504 in YAP.

[0174] In the present application, the peak intensity change can be understood as 1 H or 15The change of the N resonance absorption peak, the calculation method of the peak intensity change can be 1 and the difference between the resonance absorption peak intensity after titration / the resonance absorption peak intensity before titration.

[0175] Combination Fig. 6A and Figure 6B The published experimental results show that the YAP and TAF4 binding region includes FLTWL (FLTWL is a part of PDZ). Example 4 also further verifies the accuracy of the conclusions drawn in Examples 1 to 3.

[0176] In summary, the localization results of Examples 1 to 4 indicate that FLTWL in YAP can bind to TAF4, that is, FLTWL is the binding region of YAP and TAF4.

[0177] This completes the localization of the YAP and TAF4 binding region.

[0178] The Mediator family complex is a protein complex that can also interact with other transcription factors to regulate gene expression (also understood as transcription extension). The Mediator family complex plays an important role in cell differentiation, development, and disease. By studying the binding region of YAP and the Mediator family complex, peptide drugs can be designed based on the binding region so that the peptide drugs can bind to the Mediator family complex, limiting the role of the Mediator family complex in the transcription extension process of the target gene, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells. The following is combined with specific experiments to locate the binding region of YAP and the Mediator family complex.

[0179] First, a protein immunoblotting experiment was used to locate the binding area of ​​YAP and the Mediator family complex:

[0180] The Mediator family complexes selected in the present application embodiment include: MED15, MED23, and MED24.

[0181] Embodiment 5:

[0182] In this example, protein immunoblotting experiments were used to test the binding of YAP to MED15, YAP to MED23, and YAP to MED24. The experimental results can be found in Figure 7 .

[0183] In this example, HA was used to label YAP. Figure 7 It can be expressed as: HA-YAP; MED15 is tagged with Flag (MED15 is in Figure 7 15 in Chinese), Flag MED23 (MED23 in Figure 7 23 in Chinese), Flag MED24 (MED24 in Figure 7 In Figure 7 It can be expressed as: Flag-MED. Figure 7 (a) in the figure is the experimental result of the positive control.

[0184] See also Figure 7 In (II):

[0185] Band 71 (test electrophoresis using single protein YAP): MED15 was pre-adsorbed on the electrophoresis membrane, and HA could be detected in band 71. Flag could be detected in band 72. It can be seen that MED15 binds to YAP, that is, MED15 and YAP interact with each other.

[0186] Band 72 (test electrophoresis using single protein YAP): MED23 was pre-adsorbed on the electrophoresis membrane, and HA could be detected in band 72. Flag was not detected in band 73. It can be seen that MED23 and YAP did not bind, that is, there was no interaction between MED23 and YAP.

[0187] Band 73 (test electrophoresis using single protein YAP): MED24 was pre-adsorbed on the electrophoresis membrane, and HA could be detected in band 73. No Flag was detected in band 73, indicating that MED24 and YAP did not bind, that is, there was no interaction between MED24 and YAP.

[0188] Combination Figure 7 The experimental results show that YAP can bind to MED15.

[0189] Embodiment 6:

[0190] In order to further determine the binding region of YAP and MED15, the present invention uses a protein imprinting experiment to further test the binding of different domains of YAP to MED15.

[0191] In this example, HA was used to label YAP, and HA was used to label YAP-ΔCC (in Figure 8 HA was used to label YAP-△sIDR (YAP-△sIDR was abbreviated as △CC in Figure 8 sIDR in Chinese), HA was used to label YAP-△sTAD (YAP-△sTAD in Figure 8 MED15 was tagged with Flag. Figure 8 It can be expressed as Flag-MED15. Figure 8 (a) in the figure is the experimental result of the positive control.

[0192] See also Figure 8In (II):

[0193] Band 81 (test electrophoresis using single protein MED15): YAP was pre-adsorbed on the electrophoresis membrane of band 81, and HA could be detected on band 81. Flag was detected in band 81. It can be seen that YAP binds to Flag-tagged MED15, that is, YAP and MED15 interact with each other.

[0194] Band 82 (test electrophoresis using single protein MED15): YAP-△CC was pre-adsorbed on the electrophoresis membrane of band 82, and HA could be detected on band 82. Flag could be detected in band 82, indicating that YAP-△CC and MED15 were bound, that is, there was an interaction between YAP-△CC and MED15.

[0195] Band 83 (test electrophoresis using single protein MED15): YAP-△sIDR was pre-adsorbed on the electrophoresis membrane of band 83, and HA could be detected on band 83. Flag could be detected in band 83, indicating that YAP-△sIDR bound to MED15 and there was an interaction between YAP-△sIDR and MED15.

[0196] Band 84 (test electrophoresis using single protein MED15): YAP-△sTAD was pre-adsorbed on the electrophoresis membrane of band 84, and HA could be detected on band 84. Flag was not detected in band 84. It can be seen that YAP-△sTAD did not bind to MED15. It can be further known that after the sTAD domain was intercepted, the interaction between YAP and MED15 was destroyed. It can be inferred that the binding region of YAP and MED15 includes: sTAD.

[0197] In order to further locate the binding region of MED15 and YAP, the present invention divides MED15 into three domains. Fig. 9 , the three structural domains of MED15 are:

[0198] (1) ABD1 domain of MED15. The ABD1 domain of MED15 can be represented as: MED15-ABD1, abbreviated as ABD1. The amino acid sequence of ABD1 in MED15 is: 80-148.

[0199] (2) ABD2 domain of MED15. The ABD2 domain of MED15 can be represented as: MED15-ABD2, abbreviated as ABD2. The amino acid sequence of ABD2 in MED15 is: 310-350.

[0200] (3) ABD3 domain of MED15. The ABD3 domain of MED15 can be represented as: MED15-ABD3, abbreviated as ABD3. The amino acid sequence of ABD3 in MED15 is: 453-561.

[0201] In order to further determine the binding of YAP-sTAD to different domains of MED15, the present invention uses NMR titration experiments to further locate the binding of YAP-sTAD to different domains of MED15.

[0202] Embodiment 7:

[0203] In this example, 0.1 mM 15 N-YAP-sTAD was used as the titrant and ABD3 was used as the titrant. 15 N-YAP-sTAD 1 H- 15 N-HSQC, experimental results can be found in Fig. 10A and Fig. 10B .

[0204] exist Fig. 10A In the above, YAP-sTAD:ABD3 can be understood as the molar concentration ratio of YAP-sTAD to ABD3. This example tests the molar ratios of YAP-sTAD to ABD3 as 1:0, 1:0.5, 1:1, 1:2, and 1:4, respectively. 15 N-YAP-sTAD 1 H and 15 The resonance absorption peak position of N. When the molar ratio of YAP-sTAD to TAF4-M2 is 1:0, YAP-sTAD and TAF4-M2 do not bind, and the resonance absorption peak position at this time can be used as a benchmark.

[0205] It can be seen that after adding ABD3, 15 N-YAP-sTAD 1 H and 15 N all underwent chemical shifts, and with the increase of ABD3 molar concentration, 1 H and 15 The change of N chemical shift gradually increases. It can be inferred that YAP-sTAD interacts with ABD3, resulting in 15 N-YAP-sTAD 1 H and 15 N undergoes chemical shift. It can be further learned that the binding region of MED15 and YAP includes: ABD3.

[0206] Please continue reading Fig. 10A , 15FLTWL (F500, L501, T501, W501, L504) in N-YAP-sTAD 15 N chemical shift and 1 The H chemical shift changed significantly, which indicates that FLTWL in YAP binds to ABD3.

[0207] Fig. 10B for 15 Results of NMR titration experiment of N-YAP-sTAD and ABD3 (YAP-sTAD: ABD3 = 1:4). Fig. 10B The horizontal axis is 15 The sequence of each amino acid in N-YAP-sTAD, the ordinate is: the change in peak intensity before and after titration. The peak intensity of the amino acid sequence at 500-504 has changed, which can further verify that the binding area of ​​YAP and TAF4 includes: the domain (FLTWL) of the amino acid sequence at 500-504 in YAP.

[0208] Embodiment 8:

[0209] In order to further determine the binding of YAP-sTAD to different domains of ABD3, the present invention uses NMR titration experiments to further locate the binding of YAP-sTAD to different domains of ABD3.

[0210] This example uses 0.1 mM 15 N-MED15-ABD3 was used as the titrant and YAP-sTAD was used as the titrant. 15 N-MED15-ABD3 domain 1 H and 15 N-heteronuclear single quantum relations, experimental results can be found in Fig.11A and Fig. 11B .

[0211] exist Fig.11A middle 15 N-MED15-ABD3:YAP-sTAD can be understood as 15 The molar concentration ratio of N-MED15-ABD3 to YAP-sTAD was tested in this example: 15 When the molar ratios of N-MED15-ABD3 and YAP-sTAD were 1:0, 1:0.5, 1:1, 1:2, and 1:4, 15 N-MED15-ABD3 1 H and 15 The resonance absorption peak position of N. 15 N-MED15-ABD3: When YAP-sTAD is 1:0, 1 H and15 The resonance absorption peak position of N can be used as a benchmark.

[0212] It can be seen that after adding YAP-sTAD, 15 N-MED15-ABD3 1 H and 15 N all underwent chemical shifts, and with the increase of YAP-sTAD molar concentration, 15 N-MED15-ABD3 1 The chemical shift of H and 15 The chemical shift of N gradually increased. It can be inferred that MED15-ABD3 interacts with YAP.

[0213] Please continue reading Fig.11A , the amino acid sequence is leucine 533 (L533), 15 The amino acid sequence of N-MED15-ABD3 is lysine 538 (K538), 15 The amino acid sequence of N-MED15-ABD3 is cysteine ​​540 (TJ-C540), 15 The chemical shift of leucine (L542) at amino acid sequence 542 in N-MED15-ABD3 changed significantly, and it can be inferred that the amino acid sequence of MED15 binds to YAP in the domain 533-542.

[0214] Fig. 11B YAP-sTAD and 15 Results of NMR titration experiment of N-MED15-ABD3 ( 15 N-MED15-ABD3:YAP-sTAD=1:4). Fig. 11B The horizontal coordinate is 15 The sequence of each amino acid in N-MED15-ABD3, the ordinate is: the change in peak intensity before and after titration. The peak intensity of the amino acid sequence 533-542 has changed, which can further verify that the binding area of ​​YAP and MED15 includes: the domain of the amino acid sequence 533-542.

[0215] Surface plasmon resonance (SPR) experiment is a commonly used bioanalysis technique that can be used to measure the interaction between biomolecules (proteins). SPR determines the affinity between a protein and other substances (which may include other proteins) by measuring the resonance phenomenon of a protein on a metal surface. The affinity between a protein and a substance can be referred to as protein affinity. In the present embodiment, protein affinity can be represented by a KD value.

[0216] In the present application example, the SPR experiment was further used to measure the KD value of MED15 and YAP, and the KD value of MED15-ABD3 and YAP. The experimental results can be found in Table 2.

[0217] Table 2

[0218] Ligand / Protein Analyte / Protein KD value MED15 YAP <![CDATA[2.39e -8 ]]> MED15-ABD3 YAP <![CDATA[1.88e -8 ]]>

[0219] It can be seen from the KD values ​​in Table 2 that there are interactions between MED15 and YAP, and between MED15-ABD3 and YA. The data in Table 2 can further verify the conclusion obtained in the above embodiment: the binding region of YAP and MED15 includes: YAP-sTAD.

[0220] In summary, the data of Examples 6 to 8 and Table 2 show that the binding region of transcriptional coactivators (YAP, TAZ) and MED15 includes sTAD.

[0221] Embodiment 9:

[0222] The present application example further uses NMR titration experiments to further verify that the binding region of YAP and MED15 is FLTWL.

[0223] In this example, 0.1 mM 15 N-MED15-ABD3 was used as the titrant and FLTWL as the titrant. 15 N-MED15-ABD3 1 H and 15 The experimental results of HSQC of N can be found in Fig. 12A and Fig. 12B .

[0224] exist Fig. 12A middle 15 N-MED15-ABD3: FLTWL can be understood as 15 The molar concentration ratio of N-MED15-ABD3 to FLTWL. This example tested: 15 When the molar ratios of N-MED15-ABD3 and FLTWL were 1:0, 1:1, 1:2, 1:4, and 1:8, 15 N-MED15-ABD3 1 H and 15 The resonance absorption peak position of N. 15 N-MED15-ABD3: When FLTWL is 1:0, 1 H and 15 The chemical shift of N can be used as a reference.

[0225] It can be seen that after joining FLTWL, 15N-MED15-ABD3 1 H and 15 N all underwent chemical shifts, and with the increase of FLTWL molar concentration, 15 N-MED15-ABD3 1 The chemical shift of H and 15 The chemical shift of N gradually increased. It can be inferred that MED15-ABD3 interacts with FLTWL.

[0226] Please continue reading Fig. 12A , 15 The chemical shifts of L533, K538, TJ-C540, and L542 in N-MED15-ABD3 changed significantly. It can be inferred that the amino acid sequence of MED15-ABD3 interacts with FLTWL in the domain of 533-542. It can also be inferred that the binding region of YAP and MED15-ABD3 includes FLTWL.

[0227] Fig. 12B for 15 Results of NMR titration experiment of N-MED15-ABD3 and FLTWL ( 15 N-MED15-ABD3:FLTWL=1:8). Fig. 12B The horizontal coordinate is 15 The sequence of each amino acid in N-MED15-ABD3, the ordinate is: the change in peak intensity before and after titration. The peak intensity of the amino acid sequence 533-542 has changed, which can further verify that the binding area of ​​YAP and MED15 includes: the domain of the amino acid sequence 533-542.

[0228] In summary, the data of Examples 1 to 9 and Table 2 show that the binding region of the transcriptional coactivator (YAP / TAZ) and the downstream MED15 and TAF4 includes FLTWL. FLTWL can interact with at least one of TAF4 and MED15 to achieve the purpose of inhibiting the growth of cancer cell proliferation.

[0229] Based on the above conclusions, the present application embodiment performs amino acid mutation on FLTWL to obtain FLTWL derived peptides. The FLTWL derived peptides include: the first amino acid; the first amino acid has the same sequence number as an amino acid in FLTWL, and the amino acid in FLTWL with the same sequence number as the first amino acid is different from the first amino acid; the FLTWL derived peptide interacts with at least one of the transcription initiation factor binding protein TAF4 and the recombinant protein MED15; the FLTWL derived peptide interacts with at least one of the proteins in TAF4 and MED15.

[0230] The FLTWL-derived peptide disclosed in the present application has a similar amino acid sequence to FLTWL. The FLTWL-derived peptide interacts with at least one of TAF4 and MED15 proteins, that is, the FLTWL-derived peptide can bind to at least one of TAF4 and MED15 proteins.

[0231] The FLTWL-derived peptide disclosed in the examples of the present application has a similar amino acid sequence to FLTWL. The FLTWL-derived peptide interacts with at least one of TAF4 and MED15 proteins, that is, the FLTWL-derived peptide can bind to at least one of TAF4 and MED15 proteins.

[0232] When the FLTWL-derived peptide is combined with TAF4, the role of TAF4 in the transcription initiation process of the target gene in cancer cells can be limited, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells. When the FLTWL-derived peptide is combined with MED15, the role of MED15 in the transcription extension process of the target gene in cancer cells can be limited, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells. The FLTWL-derived peptide disclosed in the embodiment of the present application is a new type of peptide chain, which can be used in tumor drugs and can solve the problem of drug resistance of currently disclosed tumor drugs.

[0233] The FLTWL-derived peptide disclosed in the examples of the present application includes: a first amino acid having the same sequence number as an amino acid in FLTWL, and the amino acid in FLTWL having the same sequence number as the first amino acid is different from the first amino acid;

[0234] For example, for the FLTWL derivative peptide amino acid sequence: FLEWL, the amino acid number of E is 3, which is a different amino acid from T which is the amino acid number 3 of FLTWL. In FLEWL, E can be considered as the first amino acid.

[0235] The embodiments of the present application are only exemplary introductions of several examples, and the FLTWL-derived peptide includes an example of a first amino acid, and the above examples do not constitute a specific limitation. For example, in some feasible implementations, the FLTWL-derived peptide includes 2 first amino acids. In some feasible implementations, the FLTWL-derived peptide includes 3 first amino acids.

[0236] As a feasible implementation method, the FLTWL-derived peptide may also include: a second amino acid core and a third amino acid; the second amino acid has the same sequence number as an amino acid in FLTWL; the amino acid in FLTWL that has the same sequence number as the second amino acid is the same as the second amino acid; the third amino acid has the same sequence number as an amino acid in FLTWL; the amino acid in FLTWL that has the same sequence number as the third amino acid is the same as the third amino acid.

[0237] As a feasible implementation method, the amino acid sequence of the FLTWL-derived peptide includes any one of FLTFL, DLTWL, ELTWL, FWTWL, FITWL, FLEWL, and FLDWL.

[0238] The present application also discloses a polypeptide, which includes: a nuclear localization signal peptide and a FLTWL derivative peptide disclosed in the examples of the present application. The FLTWL derivative peptide is located at least one of the N-terminus of the nuclear localization signal peptide and the C-terminus of the nuclear localization signal peptide; or, the polypeptide includes: a nuclear localization signal peptide and a hydrophobic peptide FLTWL, and the hydrophobic peptide FLTWL is located at least one of the N-terminus of the nuclear localization signal peptide and the C-terminus of the nuclear localization signal peptide.

[0239] The polypeptide disclosed in the embodiment of the present application includes: a nuclear localization signal peptide. The nuclear localization signal peptide can guide the FLTWL-derived peptide / FLTWL (which can be understood as a FLTWL-derived peptide, or FLTWL) into the cell nucleus. Then, the FLTWL-derived peptide / FLTWL can bind to at least one of the proteins MED15 and TAF4 located in the cell nucleus, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0240] In the examples of the present application, the nuclear localization signal peptide can be understood as a peptide chain that has the function of guiding the FLTWL-derived peptide / FLTWL to enter the cell nucleus. The examples of the present application do not specifically limit the types of nuclear localization signal peptides, and any peptide chain that can guide the FLTWL-derived peptide / FLTWL to enter the cell nucleus can be used as a nuclear localization signal peptide in the examples of the present application.

[0241] Exemplarily, the nuclear localization signal peptide may include a peptide chain having an amino acid sequence of PKKKRKV, or a peptide chain having an amino acid sequence of MTYPRRRFRRRRHRPRSHLGQILRRRPWLVHPRHRYRWRRKNGIFNT.

[0242] The nuclear localization signal peptide having the amino acid sequence of PKKKRKV may be referred to as SV40 in the examples of the present application.

[0243] The examples of this application specifically disclose the amino terminal sequences of several polypeptides. For details, please refer to Table 3:

[0244] Table 3

[0245] In the examples of this application, the abbreviation X peptide is Amino acid sequence TJ-C8 PKKKRKVFLTWL TJ-M11 FLTWLPKKKRKVFLTWL TJ-C3 FLTFLPKKKRKVFLTFL TJ-C4 DLTWLPKKKRKVDLTWL TJ-C5 ELTWLPKKKRKVELTWL TJ-C6 FWTWLPKKKRKVFWTWL TJ-C7 FITWLPKKKRKVFITWL TJ-C9 FLEWLPKKKRKVFLEWL TJ-C10 FLDWLPKKKRKVFLDWL

[0246] It is worth noting that the examples of the present application are merely illustrative of several polypeptides having amino terminal sequences, and the above amino terminal sequences do not constitute a specific limitation, and the amino acid sequence can be set according to needs.

[0247] For example: The present application example does not specifically limit the relative positions of the nuclear localization signal peptide and the FLTWL-derived peptide / FLTWL. Exemplary:

[0248] As a feasible implementation method, a peptide chain in the FLTWL derivative peptide / FLTWL can be located on the side of the nuclear localization signal peptide near the N-terminus. Specifically, refer to TJ-C8 in Table 3. TJ-C8 can be understood as: FLTWL is located on the side of the nuclear localization signal peptide (PKKKRKV) near the N-terminus.

[0249] As a feasible implementation method, one peptide chain in the FLTWL derivative peptide / FLTWL can be located on the side of the nuclear localization signal peptide near the C-terminus. For example, FLTWL can be located on the side of the nuclear localization signal peptide (PKKKRKV) near the C-terminus, that is, the polypeptide can have the amino acid sequence of FLTWLPKKKRKV.

[0250] As a feasible implementation method, one FLTWL derivative peptide / FLTWL can be located on the side of the nuclear localization signal peptide near the N-terminus, and another FLTWL derivative peptide / FLTWL can be located on the side of the nuclear localization signal peptide near the C-terminus. For details, please refer to TJ-M11, TJ-C4, TJ-C5, TJ-C6, TJ-C7, TJ-C9, and TJ-C10 in Table 3.

[0251] It is worth noting that: TJ-C4, TJ-C5, TJ-C6, TJ-C7, TJ-C9, and TJ-C10 are only exemplary introductions of the FLTWL-derived peptides at both ends of the nuclear localization signal peptide (PKKKRKV) having the same amino acid sequence. The above examples do not constitute specific limitations. In actual applications, the FLTWL-derived peptides at both ends of the nuclear localization signal peptide (PKKKRKV) may have different amino acid sequences.

[0252] The present application also discloses a polypeptide drug, which may include: a liposome and a polypeptide disclosed in the present application. The liposome encapsulates the polypeptide. The polypeptide drug disclosed in the present application is inserted into the liposome. The liposome is similar to the cell membrane structure, so there is a strong affinity between the liposome and the cell membrane, so that the liposome can carry the polypeptide inside it into the cell.

[0253] In the process of crossing the cell membrane, the liposome is dissolved by the cell membrane, and the polypeptide inside the liposome is released into the cell. The polypeptide located in the cell can enter the cell nucleus under the guidance of the nuclear localization signal peptide and bind to at least one protein of MED15 and TAF4 located in the cell nucleus, thereby achieving the purpose of inhibiting the proliferation and growth of cancer cells.

[0254] In addition, the polypeptide drug disclosed in the examples of the present application is a new type of polypeptide drug, and the polypeptide drug disclosed in the examples of the present application has lower drug resistance.

[0255] The following is a further description of the polypeptide drug disclosed in the examples of this application in conjunction with specific experiments:

[0256] The inhibitory effect of peptide drugs on cancer cells can be expressed by half maximal inhibitory concentration (ITJ-C50). ITJ-C50 of peptide drugs can be understood as: the ratio of the number of surviving cancer cells to TJ-C100 reaches 50%, corresponding to the dosage concentration of the peptide drug. Among them, TJ-C100 can be understood as the number of surviving cancer cells when the dosage concentration is 0.

[0257] The smaller the ITJ-C50 of the peptide drug, the more significant the inhibitory effect of the peptide drug on cancer cells.

[0258] In the present application, the ITJ-C50 of several polypeptide drugs was tested based on the cell proliferation experiment (cell counting Kit-8, CCK8). The test results can be found in Fig.13 and Table 4.

[0259] Fig.13 The horizontal axis is the dosage concentration of the polypeptide drug in micromolar (μM), and the vertical axis is the number of surviving cancer cells (H1299) (cell viability).

[0260] Table 4

[0261]

[0262]

[0263] from Fig.13 From the data in Table 3, it can be seen that the ITJ-C50 of the polypeptide drug disclosed in the examples of the present application can reach below 27.73 μM. It can be seen that the polypeptide drug disclosed in the examples of the present application has a lower ITJ-C50, and the polypeptide drug disclosed in the examples of the present application has a significant inhibitory effect on cancer cells.

[0264] Embodiment 10:

[0265] The peptide drugs disclosed in the examples of this application need to enter cells to inhibit cancer cells. The examples of this application further verify the uptake effect of peptide drugs by cancer cells.

[0266] In the present application, the immunofluorescence technique was used to detect the effect of H1299 on the uptake of peptide drugs. Fig.14 and Fig.15 .

[0267] Fig.14 (a) in the figure is the image of H1299 collected before administration. Fig.14 (ii) is an image of H1299 collected after adding peptide drug TJ-M11. Fig.14 From (ii) in the figure, it can be seen that after administration, the peptide drug TJ-M11 enters the cells of H1299, which shows that the peptide drug TJ-M11 can be better taken up by H1299. Fig.14 It can also be seen from (ii) that the peptide drug TJ-M11 can enter the cell nucleus N1.

[0268] Fig.15 (a) in the figure is the image of H1299 collected before administration. Fig.15 (ii) is an image of H1299 after adding peptide drug TJ-C8. It can be seen that peptide drug TJ-C8 can be well taken up by H1299 and can enter the cell nucleus of H1299.

[0269] Combined with the results of immunofluorescence experiments, it can be seen that the polypeptide drug disclosed in the examples of the present application can be well taken up by cancer cells.

[0270] Embodiment 11:

[0271] In order to verify that the polypeptide drug disclosed in the examples of this application can inhibit the expression of target genes in TEAD family members, in the examples of this application, the mRNA expression of TEAD family members was detected by quantitative real-time PCR (qPCR) detection technology.

[0272] The TEAD family members selected in this example include: ANKRD1, CTGF, CYR61. The nuclear localization signal peptide SV40 was used as a comparative example, and the polypeptide drug TJ-M11 was used as an experimental group:

[0273] Specifically, this embodiment tests:

[0274] The mRNA expressions of ANKRD1, CTGF, and CYR6 after the addition of nuclear localization signal peptide SV40;

[0275] The mRNA expression of ANKRD1, CTGF, and CYR6 family members after the addition of the peptide drug TJ-M11.

[0276] The experimental results obtained in this example can be found in Fig.16 .

[0277] Fig.16 The horizontal axis in the figure represents the types of drug administration for TEAD family members. Fig.16 The vertical axis is the relative amount of mRNA expression (relative mRNA expression).

[0278] It can be seen that after adding the polypeptide drug, the expression amount of TEAD family member mRNA is significantly reduced, and it can be inferred that the polypeptide drug can inhibit the expression of TEAD family members. It can be further inferred that the polypeptide drug disclosed in the embodiment of the present application can inhibit the proliferation and growth of cancer cells.

[0279] Embodiment 12:

[0280] The present application example further verifies through plate cloning experiments that the polypeptide drug disclosed in the present application example has an inhibitory effect on the proliferation and growth of cancer cells.

[0281] The cancer cells selected in this example include: H1299. The nuclear localization signal peptide SV40 is used as a comparative example. The results of the plate cloning experiment can be found in Fig.17A and Fig. 17B .

[0282] Fig.17A (a) in the middle is the image of H1299 after adding SV40; Fig.17A (B) in the figure is the image of H1299 after adding peptide drug TJ-M11.

[0283] from Fig.17A The experimental results show that compared with the control example, the growth of H1299 was significantly reduced after the addition of the peptide drug TJ-M11. It can be further inferred that the peptide drug disclosed in the examples of the present application can inhibit the growth of H1299.

[0284] Fig. 17B The horizontal axis is the type of medication. Fig. 17B The vertical axis in the figure is the number of colonies after administration. The number of colonies can reflect the proliferation of H1299, and the number of colonies is positively correlated with the proliferation of H1299. Fig. 17BThe experimental results show that: compared with the control example, the number of clones / proliferation of H1299 was significantly reduced after adding the peptide drug TJ-M11. It can be further inferred that the peptide drug disclosed in the examples of the present application can inhibit the proliferation and growth of cancer cells.

[0285] Embodiment 13:

[0286] The cancer cells selected in this example include: TDCL. The nuclear localization signal peptide SV40 is used as a comparative example. The results of the plate cloning experiment can be found in Fig.18A and Fig.18B ;

[0287] Fig.18A (a) in the middle is the image of TDCL after adding SV40; Fig.18A (ii) is the image of TDCL after adding peptide drug TJ-M11. Fig.18A The experimental results show that compared with the control example, the growth of TDCL was significantly reduced after the addition of the peptide drug TJ-M11. It can be further inferred that the peptide drug disclosed in the examples of the present application can inhibit the growth of TDCL.

[0288] Fig.18B The horizontal axis is the type of medication. Fig.18B The vertical axis in the figure is the number of clones after drug administration. Fig.18B The experimental results show that compared with the control group, the number of clones / proliferation of TDCL was significantly reduced after the addition of peptide drug TJ-M11.

[0289] Based on the experimental results of Example 12 and Example 13, it can be seen that the polypeptide drug disclosed in the examples of the present application can inhibit the proliferation and growth of cancer cells.

[0290] In order to further verify the inhibitory effect of the polypeptide drug disclosed in the examples of the present application on cancer cells, the examples of the present application further tested the ITJ-C50 of the polypeptide drug on cancer cells. The specific experimental results can be found in Fig.19 and Table 5.

[0291] Table 5

[0292]

[0293] from Fig.19 From the data in Table 5, it can be seen that the ITJ-C50 of the polypeptide drug disclosed in the examples of the present application on cancer cells can reach below 27.73 μM. It can be seen that the polypeptide drug disclosed in the examples of the present application has a lower ITJ-C50, and the polypeptide drug disclosed in the examples of the present application has a significant inhibitory effect on cancer cells.

[0294] Embodiment 14:

[0295] The examples of the present application also verify the anti-tumor effect of the polypeptide drug in an animal model.

[0296] The applicant expanded the culture of the cell line TDCL derived from mouse lung adenocarcinoma and established a subcutaneous transplant tumor TDCL model.

[0297] The peptide drug TJ-M11 was selected as the experimental group, and SV40 was selected as the control group for intratumoral administration experiments. The dosage for each mouse was 5 mg / kg, once every other day until the end of the experiment.

[0298] The present invention uses a vernier caliper to measure the tumor volume of the two groups (experimental group and control group) from the eighth day of administration. The statistical data of the six groups of experiments show that the tumor volume of the experimental group is significantly smaller than that of the control group. The experimental results can be found in Fig. 20A , Fig. 20B and Fig. 20C .

[0299] Fig. 20A Tumor images of the experimental and control groups;

[0300] Fig. 20B This is a statistical diagram of the difference in tumor volume between the experimental group and the control group within 20 days of drug administration;

[0301] Fig. 20C Statistical analysis of the difference in tumor weight between the experimental group and the control group within 20 days of administration.

[0302] Fig. 20A , Fig. 20B and Fig. 20C The experimental results show that in the mouse subcutaneous transplant tumor model, the tumor weight and size of the experimental group are significantly smaller than those of the control group, which can prove that the polypeptide drug disclosed in the examples of the present application can inhibit the growth of mouse lung adenocarcinoma tumors.

[0303] Although the embodiments of the present application and their advantages are described in detail, it should be understood that various changes, substitutions and modifications can be made to the embodiments herein without departing from the spirit and scope of the embodiments of the present application as defined in the appended claims. Through the above description, any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed in the embodiments of the present application, which should be included in the protection scope of the embodiments of the application. Therefore, the protection scope of the embodiments of the application should be based on the protection scope of the claims.

Claims

1. A FLTWL-derived peptide, characterized in that The FLTWL-derived peptide comprises: a first amino acid; The first amino acid has the same sequence number as an amino acid in the FLTWL, and the amino acid in the FLTWL that has the same sequence number as the first amino acid is different from the first amino acid; The FLTWL-derived peptide interacts with at least one of the transcription initiation factor binding protein TAF4 and the recombinant protein MED15.

2. The FLTWL-derived peptide according to claim 1, characterized in that The FLTWL-derived peptide further comprises: a second amino acid core and a third amino acid; The second amino acid has the same sequence number as an amino acid in the FLTWL; the amino acid in the FLTWL that has the same sequence number as the second amino acid is the same as the second amino acid; The third amino acid has the same sequence number as an amino acid in the FLTWL; the amino acid in the FLTWL that has the same sequence number as the third amino acid is identical to the third amino acid.

3. The FLTWL-derived peptide according to claim 1 or 2, characterized in that The FLTWL-derived peptide has an amino acid sequence comprising: Any one of FLTFL, DLTWL, ELTWL, FWTWL, FITWL, FLEWL, and FLDWL.

4. The FLTWL-derived peptide according to any one of claims 1 to 3, characterized in that The FLTWL is contained in the C-terminal amino acid sequence of the transcription co-activator protein YAP: 450-504 domain.

5. The FLTWL-derived peptide according to any one of claims 1 to 3, characterized in that The FLTWL is contained in the C-terminal amino acid sequence of the transcriptional co-activator protein TAZ in the 450-504 domain.

6. A polypeptide, characterized in that The polypeptide comprises: a nuclear localization signal peptide and the FLTWL-derived peptide according to any one of claims 1 to 5, wherein the FLTWL-derived peptide is located at at least one of the N-terminus of the nuclear localization signal peptide and the C-terminus of the nuclear localization signal peptide; Or, the polypeptide comprises: the nuclear localization signal peptide and a hydrophobic polypeptide, the hydrophobic peptide is located at at least one of the N-terminus of the nuclear localization signal peptide and the C-terminus of the nuclear localization signal peptide, and the hydrophobic polypeptide has an amino acid sequence of FLTWL.

7. The polypeptide according to claim 6, characterized in that The polypeptide has an amino acid sequence comprising: Any one of PKKKRKVFLTWL, FLTWLPKKKRKV, FLTWLPKKKRKVFLTWL, DLTWLPKKKRKVDLTWL, ELTWLPKKKRKVELTWL, FWTWLPKKKRKVFWTWL, FITWLPKKKRKVFITWL, FLEWLPKKKRKVFLEWL, and FLDWLPKKKRKVFLDWL, wherein the amino acid sequence of the nuclear localization signal peptide includes PKKKRKV.

8. A polypeptide drug, characterized in that: include: Liposome and the polypeptide according to claim 6 or 7; The liposomes encapsulate the polypeptide.

9. The polypeptide drug according to claim 8, characterized in that: The half inhibitory concentration of the polypeptide drug on cancer cells is less than or equal to 27.73 μM.

10. The polypeptide drug according to claim 8 or 9, characterized in that: The polypeptide drug is used to inhibit the proliferation of cancer cells.

11. The polypeptide drug according to any one of claims 8 to 10, characterized in that: The polypeptide drug is used to inhibit the growth of cancer cells.

12. The polypeptide drug according to any one of claims 8 to 11, characterized in that: The polypeptide drug is used to inhibit the expression of target genes in cancer cells.

13. The polypeptide drug according to claim 8, characterized in that: The polypeptide drug is used to inhibit the growth of tumors.

14. The polypeptide drug according to any one of claims 8 to 13, characterized in that: The cancer cells include at least one of adenocarcinoma cells, colorectal cancer cells, and liver cancer cells.